ovarian adnexal mass Aspira Q4 Revenues up 36 Percent The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent. Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening. Aspira Q4 Revenues Up 11 Percent, Firm Inks Deal for Ovarian Cancer Detection Tech The agreement is with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz. InterVenn Biosciences to Develop Cancer Tests, Expand Services Business With New Funding Premium The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners. Aspira Eyes $11M in Private Equity Financing Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share. Mar 29, 2017 Vermillion Q4 Revenues Up 123 Percent Mar 14, 2017 Vermillion, Quest Extend, Amend Ovarian Cancer Test Deal Mar 7, 2017 Vermillion's Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1 Mar 2, 2017 Vermillion's Aspira Labs Wins Coverage from BCBS of Michigan for OVA1 Nov 10, 2016 Vermillion Q3 Revenues Up 89 Percent Sep 29, 2016 Vermillion's Aspira Labs Wins Coverage from CareFirst BCBS for OVA1 Aug 19, 2016 Vermillion Hoping New Service Business Will Boost Revenue Growth Premium Aug 10, 2016 Vermillion Q2 Revenues Up 33 Percent, OVA1 Sales Down May 16, 2016 Vermillion Q1 Revenues Down 47 Percent Apr 28, 2016 Clinical Utility Study Finds Vermillion's OVA1 Useful in Driving High-Risk Patients to Specialists Apr 18, 2016 Vermillion Receives First $2M of $4M Loan From State of Connecticut Mar 24, 2016 With OVA1 Sales Slumping, Vermillion Looks Ahead to Overa Premium Mar 24, 2016 Vermillion Posts $361K in Q4 Revenues, Large Drop in OVA1 Sales Volume Mar 21, 2016 Vermillion Receives FDA 510(k) Clearance for Overa Jan 22, 2016 Consortium Publishes Study on Ultrasound Approach to Evaluate Adnexal Masses Premium Dec 1, 2015 Vermillion Wins Medi-Cal Coverage for OVA1 Nov 20, 2015 Vermillion's Kaiser Collaboration Could Hold Keys to Broadening OVA1 Uptake Premium Nov 12, 2015 Vermillion Q3 Revenues Up 2 Percent Oct 30, 2015 With CE Mark, Vermillion Moving Toward Commercialization of Overa Test Premium Oct 26, 2015 Vermillion Receives CE Mark for Overa Load More Breaking News People in the News at Pacific Biosciences, Metabolon, NeoGenomics, More New Products Posted to GenomeWeb: Tethis, Invitae, PerkinElmer, More In Brief This Week: Thermo Fisher Scientific, Bruker, Quantum-Si, BioMérieux, More Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19 Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests Gene Expression, Histology Reveal Clues for Targeted Rheumatoid Arthritis Treatment The Scan Call for a Different Tack Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News. Wastewater Warning The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge. Can't Get in the Program Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports. Science Paper on Spatial-Controlled Genome Editing In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.